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Warm Weather and Plasmapheresis in Management of Mixed
Cryoglobulinemia
Sonia G. Ponce, MD and Peggy Beeley, MD
Department of Internal Medicine, University of New Mexico School of Medicine

INTRODUCTION:

CASE REPORT:

PLASMAPHERESIS:

Chronic infection with hepatitis C virus (HCV) is the main cause of mixed
cryoglobulinemia (CG).
Cryoglobulinemia is characterized by clonal expansion of rheumatoid factor expressing
B-cells in the liver, lymph nodes and peripheral blood resulting in the presence of
cryoglobulins in the circulation.
Cryoglobulins are cold insoluble immune complexes containing RF, polyclonal IgG, and
HCV RNA that precipitate and deposit on vascular endothelium. This can cause
cryoglobulinemic vasculitis in organs such as the skin, kidneys, and peripheral nerves.
It is unclear how B-cells become dysregulated during the course of chronic HCV
infection.

A 51-year-old male with untreated chronic HCV presented to a rural hospital
with a worsening bilateral lower extremity rash. He had recently been
diagnosed with MPGN, severe anemia, and congestive heart failure.
Cryoglobulinemic vasculitis was suspected, and the patient was referred to a
larger regional hospital for further evaluation and plasmapheresis. On
admission, the patient had pancytopenia and worsening renal function. Physical
examination was consistent with painful palpable purpura involving both lower
extremities. Initial testing showed Hep C viral load of 3.8 million, and serologic
testing confirmed the presence of cryoglobulins. After a blood transfusion,
plasmapheresis was initiated daily for 3 days then the frequency was
decreased to every other day. After 6 rounds of plasmapheresis, renal function
and the lower extremity rash had improved significantly. Hep C therapy was
considered but was not possible due to the patient’s multiple contraindications
including severe anemia, renal failure, CHF, and poor adherence to previous
medication prescriptions.
 The patient was discharged and readmitted several times due to recurrence
of painful lower extremity rash and fatigue. After each discharge, the patient
would return to his hometown at a higher altitude and with a colder climate,
likely exacerbating his CG. The patient was advised to move to a warmer
climate and to continue plasmapheresis until he was a candidate for HCV
therapy. He underwent a total of 30 sessions of plasmapheresis by the time of
his last discharge.
This case provides an example of the relative success of long term
plasmapheresis for symptom management in patients with HCV-induced CG
who are not candidates for HCV treatment.

Plasmapheresis is a technique that removes pathogenic
cryoglobulins, immune complexes and autoantibodies from the
circulation thereby improving symptomatology.
 In CG, plasmapheresis can be used as effective adjunctive therapy
to minimize rapidly progressive disease or disease with severe
cutaneous, renal and or neurologic involvement.
Periodic plasmapheresis may control levels of cryoglobulins
preventing renal deterioration and allowing a decrease in the dose of
immunosuppressant drugs and side effects.
The number and frequency of plasmapheresis sessions are not
well established and depend upon the rate of cryoglobulin synthesis
in each patient.
Common mild side effects include chills, hypoglycemia,
hypocalcemia, bronchospasm, urticaria, paresthesias, transient fever,
nausea, vomiting, mild cytopenia and hypotension. Rarely side effects
include arrhythmias and anaphylaxis.
Small studies have shown that long-term plasma exchange defined
as >25 treatments have been successful in improving renal function
and cutaneous manifestations of CG in patients who failed to
respond to conventional therapy. Only minor side effects are usually
observed, and the risk/benefit ratio for such therapy is excellent.

Hypothetical pathogenetic mechanisms of vascular damage in mixed cryoglobulinaemia. HCV core protein is linked to IgG molecules with specific anticore reactivity,
which in turn are bound to IgM molecules with rheumatoid factor activity. This multimolecular complex may result in specific binding to endothelial cells via C1q
receptor through core protein (A) or C1q (B). The same mechanism may be proposed for neutrophils attachment (C). In (D) a close contact between a circulating cell
and endothelial cell is provided in skin biopsy of a cryoglobulinemic patient.
(Sansonno, Carbone, De Re, & Dammacco, 2007)

http://kidneyblog.word
press.com/2010/05/0
9/what-is-plasmaexchange/

EPIDEMIOLOGY:
Prevalence of HCV-induced CG varies widely
Though many HCV infected patient”s serum contain cryoglobulins, not all have
cryoglobulinemic vasculitis. 30-50% of HCV positive patients have cryoglobulins.
Between 2% and 15% of cryoglobulin positive patients develop cryoglobulinemic
vasculitis.
MAJOR CLINICAL MANIFESTATIONS:
Palpable purpura primarily of the lower legs occurs in more than 90% of patients with
symptomatic HCV-induced CG.
Membrenoproliferative glomerulonephritis (MPGN) type I presents in 10-30% of
patient with chronic HCV infection. Histology exhibits subendothelial deposition of
cryoglobulin immune complexes.
Myalgia, fatigue, and arthralgias are common manifestation in chronic HC infection in
general and noted in cryoglobulinemic patients.
Neurologic manifestations include chronic sensory polyneuropathy, acute or subacute
encephalopathy, “restless leg syndrome”, and Guillain-Barré syndrome.
(Braun, Horster, Wagner, Ihrler, & Schmid, 2007)

Dermal findings in a patient with type II cryoglobulinemia. (A) Symmetrical
purpuric papular lesions on the medial aspect of the foot soles and (B)
petechial macular lesions on the dorsal aspect of the foot on presentation.
(C) Magnification of the boxed area from (A). (D) Partial healing of the foot
sole lesion after 8 weeks of oral steroid treatment. (E) Skin biopsy from the
leg, vertical section.

Renal biopsy samples of MPGN type I. (A) Electron microscopy showing
subendothelial and mesangial electron dense immune deposits. (B) Doubling
of the GBM (arrow) and loss of podocyte foot processes (asterisk). (C)
Preserved podocyte foot processes (arrow). (D) Subendothelial electron
dense immune deposits.

Plasma exchange process on the left and plasmapheresis machine on the right.

Principal sites for the production and the activity of B-cell activating factor belonging to TNF family (BAFF) in HCV-related cryoglobulinaemic patients. (A/B)
low and high magnification of BAFF protein within portal tract of liver biopsy. BAFF protein in suprabasal/squamous layer (C) in dermal vessel walls (D) of
skin biopsy tissue from patients with cryoglobulinemic vasculitis.
(Sansonno, Carbone, De Re, & Dammacco, 2007)

TREATMENT:
The treatment of HCV-induced CG vasculitis targets either HCV or
associated clinical signs and symptoms of CG.
The standard of care for HCV infection is pegylated interferon alpha 2a/2b
(PEG-INF) in combination with ribavirin (RBV).
Rituximab shows good outcomes in treatment of HCV-CG but it increases
HCV RNA, therefore recommended use is in combination with PEG-IFN and
RBV.
Contraindications for treatment include patients with:
Decompensated cirrhosis
Kidney/Liver/Heart or any other solid organ transplant
Severe depression
Pregnant females (contraception required in female)
Unstable cardiopulmonary disease
Erythropoietin-resistant anemia
Hemoglobinopathies
Current alcohol and IV drug use
Poor medication compliance
Patients with severe disease may benefit from corticosteroids, cytotoxic
medications and plasmapheresis.

http://kidneyblog.wordpress.com/2010/05/0
9/what-is-plasma-exchange/

DISCUSSION
 Plasmapheresis coupled with warm temperatures can alleviate
symptoms in HCV-induced CG, providing a window of opportunity for
patients to improve their overall health and become potential candidates
for antiviral therapy. However, there is limited data and further research
is needed to support the effectiveness of this management option.
There is no specific guidelines for treatment of HC-induced
cryoglubulinemia and optimum treatment remains the subject of great
debate.
The general approach to treatment is based on patient specific signs,
symptoms, and associated comorbidities.

Specific needs for future research include improvement in
knowledge of the mechanism by which HCV persists and the
pathogenesis of sustained lymphoproliferation with aims to create
improved therapies.
Large clinical control trials to evaluate the long term outcomes of
plasmapheresis as sole treatment in patient who are not candidates
for antiviral are much needed.
Disclosure: :
The tissue images are not from the case presented as this were not
available.
Please e-mail me for a complete bibliography and image sources:
sgponce@salud.unm.edu.

